Meeting
2021 ASCO Annual Meeting
A phase 2 study of belinostat and SGI-110 (guadecitabine) for the treatment of unresectable and metastatic conventional chondrosarcoma.
Authors
Jay Oza
Columbia University Irving Medical Center, New York, NY
Jay Oza , Shing Mirn Lee , Mia C. Weiss , Brittany L Siontis , Benjamin C. Powers , Warren Allen Chow , Wendy Magana , Tahir Sheikh , Richard Piekarz , Gary K. Schwartz , Matthew Ingham
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Bone Tumors
Clinical Trial Registration Number
04340843
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS11578)
DOI
10.1200/JCO.2021.39.15_suppl.TPS11578
Abstract #
TPS11578
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
ETCTN/NCI 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for the treatment of unresectable and metastatic conventional chondrosarcoma.
First Author: Kristine Peregrino Lacuna
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of a combination of sintilimab, bevacizumab plus gemcitabine, and albumin-bound paclitaxel for initially unresectable gallbladder carcinoma: A prospective, single-arm phase II study.
First Author: Miao Wang
Poster
2023 ASCO Annual Meeting
The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.
First Author: Jianqing Zhu
Poster
2023 ASCO Annual Meeting
A phase 2 randomized study of magrolimab combination therapy in adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): ELEVATE-TNBC.
First Author: Natalie Rainey